Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 2/20 | 0.42 |
| ▸ | GPR3 | P46089 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5483645 | 0.75 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDMAPTGLA | |
| SCHEMBL31115164 | 0.75 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDMAPTGLA | |
| SCHEMBL11173734 | 0.73 | ALDH1A1 (0.52) | KDM4EALDH1A1HPGDMAPTGLA | |
| SCHEMBL30248459 | 0.73 | ALDH1A1 (0.52) | KDM4EALDH1A1HPGDMAPTGLA | |
| SCHEMBL2617034 | 0.71 | KDM4E (0.55) | KDM4EALDH1A1HPGDMAPTGLA | |
| SCHEMBL241706 | 0.71 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDMAPTGLA | |
| SCHEMBL5245198 | 0.71 | KDM4E (0.55) | KDM4EALDH1A1HPGDMAPTGLA | |
| SCHEMBL2014207 | 0.71 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDMAPTGLA | |
| Hydrochloric Acid SCHEMBL21979894 | 0.71 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDMAPTGLA | |
| SCHEMBL2781561 | 0.71 | KDM4E (0.50) | KDM4EALDH1A1HPGDMAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4371979-A1 | FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT | Kumiai Chemical Industry Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| EP-4366733-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230357744-A1 | ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4225315-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES | Nimmune Biopharma, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230192652-A1 | PLXDC2 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4196475-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230167083-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230128450-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| EP-1932839-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-1930339-A2 | Imide compound | MITSUI CHEMICALS, INC. (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1916245-A1 | INDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-1911759-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20070259151-A1 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| US-7259260-B2 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2007-08-21 | — | — | US | disclosed |
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| US-20050208425-A1 | Imide compound and optical recording media made by using the same | YAMAMOTO CHEMICALS, INC. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1445115-A1 | IMIDE COMPOUNDS AND OPTICAL RECORDING MEDIA MADE BY USING THE SAME | Mitsui Chemicals, Inc. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128450-A1 | NLRX1 LIGANDS | NLRP3, NLRP1, NOD1 | KDM4E 4410/4885ALDH1A1 4043/4885HPGD 3819/4885 |
| US-20050208425-A1 | Imide compound and optical recording media made by using the same | CRY1, MTNR1A, TRPA1 | KDM4E 3011/4885ALDH1A1 1336/4885HPGD 3323/4885 |
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | KDM4E 855/4885ALDH1A1 1391/4885HPGD 1479/4885 |
| US-20230167083-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | KDM4E 3554/4885ALDH1A1 4156/4885HPGD 4822/4885 |
| US-20230192652-A1 | PLXDC2 LIGANDS | PLP2, PDCD1LG2, LCP2 | KDM4E 3914/4885ALDH1A1 3872/4885HPGD 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.